Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6 and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.